Chemopreventive effects of anastrozole in a premenopausal breast cancer model

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2819-2823

  Kubatka, Peter ^a   Sadlonǒvá, Vladimíra ^a   Kajo, Karol ^a   Nosálová, Gabriela ^a   Ostatníková, Daniela ^b   Adamicová, Katarína ^a  

^a University Hospital in Martin   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

Anastrozole; Aromatase inhibitors; Chemoprevention; Mammary carcinogenesis; Premenopausal; Rat

Indexed keywords

ANASTROZOLE; ESTRADIOL; METHYLNITROSOUREA; PRASTERONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; BREAST CANCER; CANCER INHIBITION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; PREMENOPAUSE; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DEHYDROEPIANDROSTERONE; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; TRIAZOLES;

EID: 55749088473     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kelsey JL and Bernstein L: Epidemiology and prevention of breast cancer. Annu Rev Public Health 17: 47-67, 1996.
2. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M and Mattiacci MR: First-line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients - A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 22: 6S, 2004.
3. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA and Lang R: Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9: 489-496, 2004.
4. Thürlimann B, Hess D, Koberle D, Senn I, Ballabeni P, Pagani O, Percy L, Aebi S, Rochlitz C and Goldhirsch A: Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85: 247-254, 2004.
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman E, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM and van de Velde C: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092, 2004.
6. Thürlimann BJ, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN and Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757, 2005.
7. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A and Sahmoud T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, tamoxifen alone or in combination) trial efficacy and safety update analysis. Cancer 98: 1802-1810, 2003.
8. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE and Chen S: Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 140: 337-343, 1992.
9. Santen RJ, Martel J, Hoagland F, Naftolin F, Roa L, Harada N, Hafer L, Zaino R and Santner SJ: Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 79: 627-632, 1994.
10. Bernstein LM, Larionov AA, Kyshtoobaeva AS, Pozharinsski KM, Semiglazov VF and Ivanova OA: Aromatase in breast cancer tissue localization and relationship with reproductive status of patients. J Cancer Res Clin Oncol 122: 495-498, 1996.
11. Bulun SE, Sharda G, Rink J, Sharma S and Simpson ER: Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metabol 91: 1273-1277, 1996.
12. Yue W, Wang JP, Hamilton CJ, Demers LM and Santen RJ: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58: 927-932, 1998.
13. Santen RJ, Yue W, Naftolin F, Mor G and Berstein L: The potential of aromatase inhibitors in breast cancer prevention. Endocr Rel Cancer 6: 235-243, 1999.
14. Wysowski DK, Comstock GW, Helsing KJ and Lau HL: Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125: 791-799, 1987.
15. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P and Pasternack BS: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190-197, 1995.
16. Dorgan JF, Longcope C, Stephenson Jr HE, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA and Schatzkin A: Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect 105: 583-585, 1997.
17. Goss PE and Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881-894, 2001.
18. Freedman OC, Verma S and demons MJ: Pre-menopusal breast cancer and aromatase inhibitors: treating a new generation of women. Breast Cancer Res Treat 99: 241-247, 2006.
19. Kubatka P, Sadloňová V, Kajo K, Nosál'ová G and Fetisovová Ž: Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis. Neoplasma 55: 42-46, 2008.
20. Russo J, Russo IH, Rogers AE, van Zwieten MJ and Gusterson B: Pathology of Tumours in Laboratory Animals. Tumours of the Rat. Tumours of the Mammary Gland. IARC Sci Publ 99: 47-78, 1990.
21. Campos SM: Aromatase inhibitors for breast cancer in post-menopausal women. Oncologist 9: 126-136, 2004.